TuHURA Biosciences (HURA) vs Tiziana Life Sciences (TLSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
TuHURA Biosciences (HURA) has outperformed Tiziana Life Sciences (TLSA) over the past year, losing 28.2% versus a loss of 64.3%. Over five years, TLSA leads with a -53.0% price change compared with -99.9% for HURA. TuHURA Biosciences is the larger company by market cap ($82.2 million vs $79.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HURA | TLSA |
|---|---|---|
| Share price | $1.25 | $0.6206 |
| Market cap | $82.20M | $79.45M |
| 1-day change | -8.09% | -8.14% |
| YTD return | +65.13% | -58.35% |
| 1-year return | -28.16% | -64.33% |
| 5-year return | -99.91% | -52.98% |
| EPS (TTM) | $-0.50 | $-0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Net income (latest FY) | $-30.05M | $-11.86M |
| 52-week high | $3.43 | $1.90 |
| 52-week low | $0.41 | $0.55 |
| Distance from 52-week high | -63.56% | -67.34% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +543.20% | +1203.58% |
| Average volume | 329.76K | 606.04K |
| Shares outstanding | 65.76M | 128.03M |
| Employees | 22 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HURA has outperformed TLSA by 36.2 percentage points over the past year.
About TuHURA Biosciences
HURA stock →TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
About Tiziana Life Sciences
TLSA stock →Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
HURA vs TLSA FAQ
Which is bigger, TuHURA Biosciences or Tiziana Life Sciences?
TuHURA Biosciences (HURA) is larger, with a market capitalization of $82.20M compared with $79.45M for Tiziana Life Sciences (TLSA).
Which stock has performed better over the past year, HURA or TLSA?
HURA returned -28.16% over the past 12 months, compared with -64.33% for TLSA (price return, excluding dividends). Past performance does not predict future results.
Are TuHURA Biosciences and Tiziana Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.